Su questa pagina
01DGX prezzo
02Snapshot
03Grafico
04Split azionari
05Chi siamo
06Performance
07Valutazione e rapporti
13Dividendi
14Utili
15Fondamentali Completi
16Bilanci
17Proprietari istituzionali (13F)
18Attivisti e proprietari del 5%+
19Insider aziendali
20Proprietà ETF
21Consenso
22Peer
23Notizie
26Le Mie Metriche
DGX Quest Diagnostics Incorporated Common Stock
NYSE · Health Care · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Lug 23, 2026
$233,33
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$171,18minimo 52 sett.
$248,84massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$25.67B
P/E (TTM)
24.8
EPS (TTM)
$9.42
Ricavi (TTM)
$11.56B
i tuoi badge
Intervallo 52 sett.
$171–$249
Rating Analisti
HOLD
Prezzo Obiettivo
$248
P/E
24.8
ROE
14.4%
Margine di Profitto Netto
9.2%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
DGX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$233.33
Capitalizzazione di Mercato (MRQ)
$25.67B
P/E (TTM)
24.8
EPS (TTM)
$9.42
Ricavi (TTM)
$11.56B
Rendimento div.
1.4%
ROE (TTM)
14.4%
D/E Debito/Patrimonio (MRQ)
0.8
Intervallo 52 sett.
$171–$249
DGX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Split azionari
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 21 Giugno 2005 | 2-for-1 | Avanti |
| 01 Giugno 2001 | 2-for-1 | Avanti |
Informazioni su Quest Diagnostics Incorporated Common Stock Panoramica della società da Wikipedia
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealth Care
industriaHealth Care
dipendenti46.000
paeseUS
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$11.04B2016-12-31 → 2025-12-31
EPS$8.752016-12-31 → 2025-12-31
Flusso di cassa libero$1.36B2016-12-31 → 2025-12-31
Margine netto9.2%2016-12-31 → 2025-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | DGX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | 24.8media 5 anni ≈17.7 | ≈17.7 | 23.3 | Sottovalutato | |
| P/S (TTM) | 2.2media 5 anni ≈1.7 | ≈1.7 | 1.3 | Sopravvalutato | |
| P/B (MRQ) | 3.4media 5 anni ≈2.7 | ≈2.7 | 2.9 | Valore equo | |
| EV / EBITDA | 14.7media 5 anni ≈11.0 | ≈11.0 | 11.4 | Valore equo | |
| Prezzo / FCF (TTM) | 19.0media 5 anni ≈14.9 | ≈14.9 | · | · | |
| Prezzo / Flusso di cassa (TTM) | 13.5media 5 anni ≈10.8 | ≈10.8 | 9.8 | Valore equo | |
| EV / Revenue (EV / Ricavi) | 2.8media 5 anni ≈2.2 | ≈2.2 | · | · | |
| EV / FCF | 22.9media 5 anni ≈18.8 | ≈18.8 | · | · | |
| Prezzo / Valore contabile tangibile (MRQ) | 4.4 | · | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | DGX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | 14.1%media 5 anni ≈15.6% | ≈15.6% | 8.3% | Di prim'ordine | |
| Margine EBITDA (TTM) | 19.1%media 5 anni ≈20.2% | ≈20.2% | 8.8% | Di prim'ordine | |
| Margine ante imposte (TTM) | 12.1%media 5 anni ≈14.5% | ≈14.5% | 3.8% | Di prim'ordine | |
| Margine di Profitto Netto (TTM) | 9.2%media 5 anni ≈11.0% | ≈11.0% | 5.1% | Di prim'ordine | |
| ROA (TTM) | 6.5%media 5 anni ≈8.0% | ≈8.0% | 4.0% | Di prim'ordine | |
| ROE (TTM) | 14.4%media 5 anni ≈17.4% | ≈17.4% | 12.5% | In linea | |
| ROIC | 9.2%media 5 anni ≈11.0% | ≈11.0% | 9.2% | In linea |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | DGX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | 0.8media 5 anni ≈0.8 | ≈0.8 | 0.4 | Debito elevato | |
| Rapporto corrente (MRQ) | 1.6media 5 anni ≈1.2 | ≈1.2 | 1.4 | Liquidità elevata | |
| Quick Ratio | 0.8media 5 anni ≈1.0 | ≈1.0 | 0.8 | Liquidità elevata | |
| Debito a lungo termine / Patrimonio netto (MRQ) | 0.7media 5 anni ≈0.7 | ≈0.7 | 0.7 | Debito elevato |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | DGX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | 11.8%media 5 anni ≈3.6% | ≈3.6% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | 3.7%media 5 anni ≈0.06% | ≈0.06% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 3.2% | · | · | · | |
| EPS YoY | 13.8%media 5 anni ≈2.0% | ≈2.0% | · | · | |
| Net Income YoY (Utile Netto YoY) | 13.9%media 5 anni ≈-1.4% | ≈-1.4% | · | · | |
| EPS CAGR 3Y (CAGR EPS 3 anni) | 3.2%media 5 anni ≈-9.4% | ≈-9.4% | · | · | |
| EPS CAGR 5Y (CAGR EPS 5 anni) | -3.5% | · | · | · | |
| Net Income CAGR 3Y (CAGR Utile Netto 3 anni) | 1.6%media 5 anni ≈-12.8% | ≈-12.8% | · | · | |
| Net Income CAGR 5Y (CAGR Utile Netto 5 anni) | -7.1% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | DGX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.7media 5 anni ≈0.7 | ≈0.7 | 1.2 | Debole | |
| Inventory Turnover (Rotazione delle scorte) | 39.1media 5 anni ≈33.9 | ≈33.9 | 15.6 | Di prim'ordine | |
| Receivables Turnover (Rotazione dei crediti) | 8.1media 5 anni ≈7.7 | ≈7.7 | 10.5 | Debole | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$239.9K | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Dividendi Rendimento, payout ratio, storico dividendi, CAGR 5Y
Dividend Yield1.4%
Rapporto di Distribuzione Utili35.6%
Pagamento annualizzato≈$3.44
CAGR Dividendi 5Y≈7.4%
Striscia di crescita≈14
| Data ex-dividendo | Importo | Valuta | Rendimento |
|---|---|---|---|
| Lug 8, 2026 | $0,86 | USD | ≈1.6% |
| Apr 6, 2026 | $0,86 | USD | ≈1.6% |
| Gen 13, 2026 | $0,80 | USD | ≈1.8% |
| Ott 3, 2025 | $0,80 | USD | ≈1.8% |
| Lug 7, 2025 | $0,80 | USD | ≈1.8% |
| Apr 7, 2025 | $0,80 | USD | ≈1.9% |
| Gen 14, 2025 | $0,75 | USD | ≈2.0% |
| Ott 4, 2024 | $0,75 | USD | ≈2.0% |
| Lug 8, 2024 | $0,75 | USD | ≈2.1% |
| Apr 5, 2024 | $0,75 | USD | ≈2.2% |
| Gen 16, 2024 | $0,71 | USD | ≈2.1% |
| Ott 5, 2023 | $0,71 | USD | ≈2.3% |
| Lug 10, 2023 | $0,71 | USD | ≈2.0% |
| Apr 6, 2023 | $0,71 | USD | ≈1.9% |
| Gen 17, 2023 | $0,66 | USD | ≈1.8% |
| Ott 3, 2022 | $0,66 | USD | ≈2.1% |
| Lug 5, 2022 | $0,66 | USD | ≈1.9% |
| Apr 5, 2022 | $0,66 | USD | ≈1.9% |
| Gen 18, 2022 | $0,62 | USD | ≈1.8% |
| Ott 4, 2021 | $0,62 | USD | ≈1.7% |
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
3.6%
Prossimo report
Ott 19, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Lug 20, 2026 | $3.12 | $2.85 | 9.3% |
| 31 Marzo 2026 | $2.50 | $2.37 | 5.5% | |
| 31 Dicembre 2025 | $2.42 | $2.38 | 1.5% | |
| 30 Settembre 2025 | $2.60 | $2.53 | 2.8% | |
| 30 Giugno 2025 | $2.62 | $2.60 | 0.93% | |
| 31 Marzo 2025 | $2.21 | $2.17 | 1.7% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $65.18 | $61.06 | $56.82 | $53.09 | $54.15 | $50.82 | $42.41 | $38.64 | $36.45 | $33.78 | $32.76 | $29.87 | |
| Revenue / Share | $97.65 | $87.36 | $81.88 | $83.75 | $84.28 | $69.39 | $56.81 | $54.18 | $55.06 | $52.92 | $51.68 | $51.28 | |
| Cash Flow / Share | $16.69 | $11.81 | $11.26 | $14.56 | $17.45 | $14.74 | $9.14 | $8.63 | $8.39 | $7.53 | $5.59 | $6.47 | |
| Cash / Share | $3.82 | $4.95 | $6.18 | $2.84 | $7.33 | $8.71 | $8.96 | $1.00 | $1.01 | $2.62 | $0.93 | $1.33 | |
| Dividend / Share | · | · | · | · | · | · | · | · | $1.80 | $1.65 | $1.52 | $1.32 | |
| EPS (TTM) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | · | 112,000,000 | 112,000,000 | 111,000,000 | · | 112,000,000 | 111,000,000 | 111,000,000 | · | 112,000,000 | 112,000,000 | 112,000,000 | · | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | · | 113,000,000 | 113,000,000 | 113,000,000 | · | 113,000,000 | 112,000,000 | 112,000,000 | · | 114,000,000 | 114,000,000 | 113,000,000 | · | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $68.33 | $66.36 | · | $65.39 | $64.54 | $61.87 | · | $60.79 | $59.61 | $57.95 | · | $57.37 | $55.79 | $54.02 | · | $54.69 | |
| Revenue / Share | $27.17 | $25.85 | · | $24.92 | $24.43 | $23.47 | · | $22.02 | $21.40 | $21.12 | · | $20.13 | $20.51 | $20.63 | · | $21.07 | |
| Cash Flow / Share | · | $2.48 | · | · | · | $2.78 | · | · | · | $1.38 | · | · | · | $0.83 | · | · | |
| Cash / Share | $5.69 | $3.54 | · | $3.89 | $2.85 | $1.68 | · | $6.82 | $2.44 | $4.27 | · | $1.28 | $1.12 | $1.56 | · | $6.14 | |
| Dividend / Share | $0.86 | $0.86 | $0.80 | $0.80 | $0.80 | $0.80 | $0.75 | $0.75 | $0.75 | $0.75 | $0.71 | $0.71 | $0.71 | $0.71 | $0.66 | $0.66 | |
| EPS (TTM) | $9.42 | $9.05 | · | $8.52 | $8.35 | $7.91 | · | $7.44 | $7.41 | $7.43 | · | $6.71 | $6.92 | $6.83 | · | $10.16 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.56B | $11.28B | · | $10.85B | $10.52B | $10.16B | · | $9.54B | $9.35B | $9.29B | · | $9.30B | $9.49B | $9.60B | · | $10.29B | |
| Net Income TTM | $1.06B | $1.02B | · | $969M | $950M | $897M | · | $841M | $840M | $846M | · | $763M | $794M | $793M | · | $1.24B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 22.5 | 21.7 | · | 22.4 | 21.5 | 21.4 | · | 20.9 | 18.5 | 17.9 | · | 18.2 | 20.3 | 20.7 | · | 12.1 | |
| P/S | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.5 | 1.7 | 1.7 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 2.0 | 1.9 | 1.8 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Dividend Yield | 1.6% | 1.6% | · | 1.6% | 1.7% | 1.8% | · | 1.9% | 2.1% | 2.2% | · | 2.3% | 1.9% | 1.9% | · | 2.2% | |
| Earnings Yield | 4.4% | 4.6% | · | 4.5% | 4.7% | 4.7% | · | 4.8% | 5.4% | 5.6% | · | 5.5% | 4.9% | 4.8% | · | 8.3% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · | |
| Annual Payout | $363M | $357M | · | $347M | $342M | $336M | · | $327M | $323M | $319M | · | $309M | $307M | $305M | · | $307M |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Margine Operativo % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Utile netto | $992M | $871M | $854M | $946M | $2.00B |
| EPS Diluito | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Rapporto corrente | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $1.36B | $909M | $864M | $1.31B | $1.83B |
Proprietari istituzionali (13F) 1.170 filer · $23.1B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
1.170
Valore detenuto
$23.1B
Nuove posizioni
118
Posizioni chiuse
64
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 118 (-23 vs trimestre precedente) | 64 (-18 vs trimestre precedente) | 430 (+89 vs trimestre precedente) | 343 (-26 vs trimestre precedente) | +3.8M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $2.497.458.052 | 14.392.082 | 10,79% | Azioni |
| BlackRock, Inc. | $1.965.923.399 | 9.275.411 | 8,49% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.533.117.858 | 7.233.394 | 6,62% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.299.474.988 | 6.131.045 | 5,61% | Azioni |
| STATE STREET CORP | $1.169.252.484 | 5.516.643 | 5,05% | Azioni |
| Boston Partners | $1.004.552.880 | 4.744.473 | 4,34% | Azioni |
| JPMORGAN CHASE & CO | $748.586.197 | 3.520.438 | 3,23% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $662.582.607 | 3.137.873 | 2,86% | Azioni |
| MORGAN STANLEY | $521.503.271 | 2.460.497 | 2,25% | Azioni |
| EdgePoint Investment Group Inc. | $476.372.038 | 2.247.568 | 2,06% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $421.376.156 | 1.988.048 | 1,82% | Azioni |
| BANK OF AMERICA CORP /DE/ | $410.151.497 | 1.935.133 | 1,77% | Azioni |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400.206.122 | 1.888.207 | 1,73% | Azioni |
| WELLS FARGO & COMPANY/MN | $371.171.119 | 1.751.220 | 1,60% | Azioni |
| Davis Selected Advisers | $329.781.509 | 1.555.612 | 1,42% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $311.037.928 | 1.467.506 | 1,34% | Azioni |
| NORGES BANK | $298.133.109 | 1.406.620 | 1,29% | Azioni |
| FMR LLC | $296.462.102 | 1.398.735 | 1,28% | Azioni |
| Invesco Ltd. | $292.303.423 | 1.379.115 | 1,26% | Azioni |
| NORTHERN TRUST CORP | $238.963.873 | 1.127.454 | 1,03% | Azioni |
| GOLDMAN SACHS GROUP INC | $208.282.052 | 982.694 | 0,90% | Azioni |
| UBS Group AG | $188.403.627 | 888.906 | 0,81% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $173.422.135 | 818.220 | 0,75% | Azioni |
| M&G PLC | $168.677.800 | 795.650 | 0,73% | Azioni |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $165.917.256 | 846.603 | 0,72% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $163.988.047 | 773.711 | 0,71% | Azioni |
| AMERIPRISE FINANCIAL INC | $161.076.730 | 759.975 | 0,70% | Azioni |
| Legal & General Group Plc | $151.986.161 | 717.085 | 0,66% | Azioni |
| Bank of New York Mellon Corp | $133.388.337 | 629.339 | 0,58% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $131.756.386 | 621.639 | 0,57% | Azioni |
| DEUTSCHE BANK AG\ | $124.180.445 | 585.895 | 0,54% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $122.662.706 | 625.894 | 0,53% | Azioni |
| Nuveen, LLC | $119.503.667 | 563.830 | 0,52% | Azioni |
| PRINCIPAL FINANCIAL GROUP INC | $109.630.811 | 517.225 | 0,47% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $107.196.222 | 505.762 | 0,46% | Azioni |
| Amundi | $105.710.274 | 498.751 | 0,46% | Azioni |
| Woodline Partners LP | $102.974.000 | 485.841 | 0,44% | Azioni |
| FIDUCIARY MANAGEMENT INC /WI/ | $102.489.906 | 483.557 | 0,44% | Azioni |
| Artemis Investment Management LLP | $99.175.856 | 467.921 | 0,43% | Azioni |
| CRAWFORD INVESTMENT COUNSEL INC | $97.514.204 | 460.081 | 0,42% | Azioni |
| BARCLAYS PLC | $95.107.474 | 448.726 | 0,41% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $90.834.224 | 428.564 | 0,39% | Azioni |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $88.822.918 | 417.715 | 0,38% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $83.772.178 | 395.245 | 0,36% | Azioni |
| M.D. Sass, LLC | $76.397.960 | 360.453 | 0,33% | Azioni |
| Qube Research & Technologies Ltd | $72.783.206 | 343.398 | 0,31% | Azioni |
| MACKENZIE FINANCIAL CORP | $70.641.875 | 333.295 | 0,31% | Azioni |
| Advisors Capital Management, LLC | $69.429.626 | 327.575 | 0,30% | Azioni |
| CITIGROUP INC | $66.888.058 | 315.584 | 0,29% | Azioni |
| Swiss National Bank | $65.683.305 | 309.900 | 0,28% | Azioni |
Attivisti e proprietari del 5%+ 13 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18 Maggio 2011 | · | Deposito iniziale | M&A / vendita | SEC |
| Persona segnalante non divulgata | 01 Febbraio 2011 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 20 Marzo 2009 | · | Deposito iniziale | · | SEC |
| GlaxoSmithKline plc ×2 depositi | 18 Settembre 2008 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 16 Febbraio 2007 | · | Deposito iniziale | · | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 depositi | 19 Gennaio 2006 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 15 Dicembre 2004 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 29 Giugno 2004 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 24 Giugno 2002 | · | Deposito iniziale | M&A / vendita | SEC |
| Persona segnalante non divulgata | 22 Maggio 2002 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 12 Aprile 2002 | · | Deposito iniziale | M&A / vendita | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 depositi | 01 Novembre 2001 | · | Deposito iniziale | M&A / vendita | SEC |
| Persona segnalante non divulgata | 14 Maggio 2001 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 52 insider · 26 dirigenti · 26 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 01 Settembre 2026 S | 122.423 | 0 | 6 | $-17.083.502 |
| Surya N Mohapatra | Chairman, President & CEO | 30 Aprile 2012 F | 243.713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22 Luglio 2026 A | 33.478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 07 Marzo 2022 F | 98.981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 05 Marzo 2013 F | 126.722 | 0 | 0 | $0 |
| Michael E Prevoznik | SVP & General Counsel | 28 Agosto 2026 M | 36.557 | 0 | 6 | $-6.649.682 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28 Luglio 2026 S | 10.335 | 0 | 2 | $-1.864.971 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 Luglio 2026 L | 13.557 | 0 | 2 | $-2.167.772 |
| Patrick Plewman | SVP for Diagnostic Services | 22 Luglio 2026 L | 15.293 | 0 | 4 | $-2.025.174 |
| Catherine T. Doherty | EVP, Regional Businesses | 05 Marzo 2026 S | 67.122 | 0 | 8 | $-6.964.749 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 04 Marzo 2026 F | 35.196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24 Settembre 2024 F | 4.673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 07 Marzo 2022 F | 48.391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17 Febbraio 2021 A | 29.045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 01 Marzo 2019 F | 6.261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 08 Marzo 2018 M | 31.757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 01 Marzo 2018 G | 37.760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 02 Marzo 2015 F | 11.837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13 Febbraio 2014 A | 19.890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31 Marzo 2013 F | 9.569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29 Febbraio 2012 F | 89.232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16 Giugno 2011 M | 47.150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12 Febbraio 2007 A | 12.974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12 Febbraio 2007 A | 31.079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12 Febbraio 2007 A | · | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28 Febbraio 2004 F | 49.609 | 0 | 0 | $0 |
| Timothy C Wentworth | Direttore | 01 Ottobre 2026 A | 1.358 | 0 | 0 | $0 |
| Wright Lassiter III | Direttore | 22 Luglio 2026 L | 10.323 | 0 | 0 | $0 |
| Vicky B Gregg | Direttore | 22 Luglio 2026 A | 18.386 | 0 | 1 | $-239.700 |
| Robert B Carter | Direttore | 22 Luglio 2026 L | 3.864 | 0 | 0 | $0 |
| Timothy L Main | Direttore | 22 Luglio 2026 L | 22.460 | 0 | 0 | $0 |
| Luis Diaz | Direttore | 20 Maggio 2026 A | 5.196 | 0 | 0 | $0 |
| Tracey Doi | Direttore | 20 Maggio 2026 A | 7.748 | 0 | 0 | $0 |
| Timothy M Ring | Direttore | 20 Maggio 2026 A | 31.140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Direttore | 20 Maggio 2026 A | 31.005 | 0 | 1 | $-270.317 |
| Gail R Wilensky | Direttore | 17 Maggio 2023 A | 20.506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Direttore | 06 Marzo 2023 F | 389.597 | 0 | 0 | $0 |
| Helen Torley | Direttore | 25 Maggio 2021 A | 6.260 | 0 | 0 | $0 |
| Daniel Stanzione | Direttore | 23 Novembre 2020 S | 28.349 | 0 | 0 | $0 |
| Jenne K Britell | Direttore | 04 Giugno 2018 G | 14.479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Direttore | 29 Maggio 2018 S | 6.000 | 0 | 0 | $0 |
| John B Ziegler | Direttore | 22 Febbraio 2017 S | 16.557 | 0 | 0 | $0 |
| John C Baldwin MD | Direttore | 12 Agosto 2015 S | 12.949 | 0 | 0 | $0 |
| William F Buehler | Direttore | 12 Febbraio 2014 M | 26.225 | 0 | 0 | $0 |
| GSK plc | Direttore | 31 Gennaio 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Direttore | 06 Maggio 2010 A | 9.334 | 0 | 0 | $0 |
| William R Grant | Direttore | 01 Aprile 2007 A | 3.334 | 0 | 0 | $0 |
| James F Flaherty III | Direttore | 04 Maggio 2006 A | 1.667 | 0 | 0 | $0 |
| Kenneth D Brody | Direttore | 28 Aprile 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Direttore | 01 Aprile 2004 A | 2.627 | 0 | 0 | $0 |
| Denise M Morrison | · | 20 Maggio 2026 A | 11.929 | 0 | 0 | $0 |
| FREEMAN KENNETH W/NJ | · | 14 Dicembre 2004 F | 216.187 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 133 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| IHF · iShares Trust | 3,75% | 212.725 SH | 11 Settembre 2026 | Giornaliero |
| RW · EA Series Trust | 2,50% | 1.865 NS | 31 Luglio 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,62% | 61.132 SH | 02 Ottobre 2026 | Giornaliero |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,49% | 67.178 NS | 31 Luglio 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,27% | 11.113 SH | 02 Ottobre 2026 | Giornaliero |
| NUDV · Nushares ETF Trust | 1,09% | 2.338 NS | 31 Luglio 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,97% | 637 NS | 31 Luglio 2026 | N-PORT |
| SPLV · Invesco Exchange-Traded Fund Trust … | 0,88% | 263.082 SH | 02 Ottobre 2026 | Giornaliero |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,78% | 4.469 SH | 02 Ottobre 2026 | Giornaliero |
| JOET · Virtus ETF Trust II | 0,78% | 8.139 NS | 31 Luglio 2026 | N-PORT |
| ESMV · iShares Trust | 0,70% | 236 SH | 11 Settembre 2026 | Giornaliero |
| QLV · FlexShares Trust | 0,63% | 4.452 NS | 31 Luglio 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,60% | 1.903 NS | 31 Luglio 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,46% | 369.448 NS | 31 Luglio 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,43% | 8.600 NS | 31 Luglio 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,43% | 8.453 NS | 31 Luglio 2026 | N-PORT |
| IYH · iShares Trust | 0,41% | 64.629 SH | 11 Settembre 2026 | Giornaliero |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711.079 SH | 19 Agosto 2026 | Giornaliero |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,38% | 22.688 NS | 31 Luglio 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,37% | 52.313 NS | 31 Luglio 2026 | N-PORT |
| IMCV · iShares Trust | 0,36% | 18.030 SH | 11 Settembre 2026 | Giornaliero |
| SUSA · iShares Trust | 0,34% | 59.240 SH | 11 Settembre 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,34% | 330.273 SH | 19 Agosto 2026 | Giornaliero |
| IXJ · iShares Trust | 0,32% | 58.047 SH | 11 Settembre 2026 | Giornaliero |
| DFLV · Dimensional ETF Trust | 0,30% | 87.905 NS | 31 Luglio 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,30% | 19.944 NS | 31 Luglio 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,30% | 2.178 NS | 31 Luglio 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,27% | 3.540 NS | 31 Luglio 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,26% | 9.337 NS | 31 Luglio 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,26% | 27.542 NS | 31 Luglio 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,25% | 7.574.000 | 02 Ottobre 2026 | Giornaliero |
| IWS · iShares Trust | 0,25% | 165.299 SH | 11 Settembre 2026 | Giornaliero |
| ESUM · Strategy Shares | 0,24% | 1.901 NS | 31 Luglio 2026 | N-PORT |
| SIZE · iShares Trust | 0,24% | 4.359 SH | 11 Settembre 2026 | Giornaliero |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2.398.948 SH | 19 Agosto 2026 | Giornaliero |
| VFMV · VANGUARD WELLINGTON FUND | 0,22% | 4.307 SH | 19 Agosto 2026 | Giornaliero |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 829.766 SH | 02 Ottobre 2026 | Giornaliero |
| ACWV · iShares, Inc. | 0,20% | 28.973 SH | 11 Settembre 2026 | Giornaliero |
| EUSA · iShares, Inc. | 0,19% | 16.140 SH | 11 Settembre 2026 | Giornaliero |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,19% | 1.371 NS | 31 Luglio 2026 | N-PORT |
| IWR · iShares Trust | 0,19% | 452.857 SH | 11 Settembre 2026 | Giornaliero |
| IMCB · iShares Trust | 0,18% | 12.959 SH | 11 Settembre 2026 | Giornaliero |
| MTUM · iShares Trust | 0,16% | 168.369 SH | 11 Settembre 2026 | Giornaliero |
| DFVX · Dimensional ETF Trust | 0,16% | 3.609 NS | 31 Luglio 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,15% | 97.399 NS | 31 Luglio 2026 | N-PORT |
| ESLG · Strategy Shares | 0,15% | 146 NS | 31 Luglio 2026 | N-PORT |
| XOEF · iShares Trust | 0,15% | 140 SH | 11 Settembre 2026 | Giornaliero |
| CATH · Global X Funds | 0,12% | 6.867 NS | 31 Luglio 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,12% | 165.000 | 01 Ottobre 2026 | Giornaliero |
| ROUS · Lattice Strategies Trust | 0,12% | 3.633 NS | 31 Luglio 2026 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0,11% | 115.253 SH | 02 Ottobre 2026 | Giornaliero |
| EVUS · iShares Trust | 0,11% | 1.865 SH | 11 Settembre 2026 | Giornaliero |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,10% | 625.384 SH | 19 Agosto 2026 | Giornaliero |
| VYM · VANGUARD WHITEHALL FUNDS | 0,10% | 440.583 SH | 19 Agosto 2026 | Giornaliero |
| DGRO · iShares Trust | 0,10% | 179.879 SH | 11 Settembre 2026 | Giornaliero |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 3.271 SH | 02 Ottobre 2026 | Giornaliero |
| PFM · Invesco Exchange-Traded Fund Trust | 0,09% | 3.153 SH | 02 Ottobre 2026 | Giornaliero |
| VTV · VANGUARD INDEX FUNDS | 0,09% | 1.051.572 SH | 19 Agosto 2026 | Giornaliero |
| DXUV · Dimensional ETF Trust | 0,09% | 2.092 NS | 31 Luglio 2026 | N-PORT |
| CRBN · iShares Trust | 0,09% | 4.406 SH | 11 Settembre 2026 | Giornaliero |
| DCOR · Dimensional ETF Trust | 0,09% | 12.279 NS | 31 Luglio 2026 | N-PORT |
| IVE · iShares Trust | 0,09% | 183.297 SH | 11 Settembre 2026 | Giornaliero |
| IUSV · iShares Trust | 0,08% | 97.344 SH | 11 Settembre 2026 | Giornaliero |
| DFAC · Dimensional ETF Trust | 0,08% | 167.227 NS | 31 Luglio 2026 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,08% | 25.423 SH | 19 Agosto 2026 | Giornaliero |
| CHRI · Global X Funds | 0,08% | 27 NS | 31 Luglio 2026 | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0,08% | 1.095 NS | 31 Luglio 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,08% | 3.155 SH | 02 Ottobre 2026 | Giornaliero |
| SUSL · iShares Trust | 0,08% | 3.907 SH | 11 Settembre 2026 | Giornaliero |
| ILCV · iShares Trust | 0,07% | 4.337 SH | 11 Settembre 2026 | Giornaliero |
| DSI · iShares Trust | 0,07% | 16.854 SH | 11 Settembre 2026 | Giornaliero |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,07% | 66.643 SH | 19 Agosto 2026 | Giornaliero |
| IWD · iShares Trust | 0,07% | 245.078 SH | 11 Settembre 2026 | Giornaliero |
| HDUS · Lattice Strategies Trust | 0,07% | 586 NS | 31 Luglio 2026 | N-PORT |
| EGLE · Global X Funds | 0,06% | 6 NS | 31 Luglio 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0,06% | 3 NS | 31 Luglio 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,06% | 24.838 SH | 02 Ottobre 2026 | Giornaliero |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,06% | 24.491 SH | 02 Ottobre 2026 | Giornaliero |
| DFSU · Dimensional ETF Trust | 0,05% | 5.056 NS | 31 Luglio 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,05% | 26.447 NS | 31 Luglio 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,05% | 9.857 SH | 02 Ottobre 2026 | Giornaliero |
| TOPC · iShares Trust | 0,05% | 68 SH | 11 Settembre 2026 | Giornaliero |
| XVV · iShares Trust | 0,04% | 1.285 SH | 11 Settembre 2026 | Giornaliero |
| XYLD · Global X Funds | 0,04% | 6.096 NS | 31 Luglio 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,04% | 3.119 SH | 02 Ottobre 2026 | Giornaliero |
| BKLC · BNY Mellon ETF Trust | 0,04% | 9.574 NS | 31 Luglio 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 15.319 NS | 31 Luglio 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0,04% | 2.875.103 SH | 19 Agosto 2026 | Giornaliero |
| VV · VANGUARD INDEX FUNDS | 0,04% | 129.285 SH | 19 Agosto 2026 | Giornaliero |
| ESGV · VANGUARD WORLD FUND | 0,04% | 24.972 SH | 19 Agosto 2026 | Giornaliero |
| TOV · EA Series Trust | 0,04% | 426 NS | 31 Luglio 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0,04% | 5.593 NS | 31 Luglio 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,04% | 1.876 NS | 31 Luglio 2026 | N-PORT |
| XYLG · Global X Funds | 0,04% | 109 NS | 31 Luglio 2026 | N-PORT |
| XCLR · Global X Funds | 0,04% | 6 NS | 31 Luglio 2026 | N-PORT |
| IVV · iShares Trust | 0,04% | 1.392.389 SH | 11 Settembre 2026 | Giornaliero |
| PBP · Invesco Exchange-Traded Fund Trust | 0,04% | 655 SH | 02 Ottobre 2026 | Giornaliero |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,04% | 19.201 SH | 02 Ottobre 2026 | Giornaliero |
| XTR · Global X Funds | 0,04% | 8 NS | 31 Luglio 2026 | N-PORT |
| ILCB · iShares Trust | 0,04% | 2.144 SH | 11 Settembre 2026 | Giornaliero |
| XRMI · Global X Funds | 0,04% | 82 NS | 31 Luglio 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,04% | 33.588 NS | 31 Luglio 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,04% | 417 NS | 31 Luglio 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,04% | 2.663 NS | 31 Luglio 2026 | N-PORT |
| IWB · iShares Trust | 0,04% | 76.198 SH | 11 Settembre 2026 | Giornaliero |
| VOXP · Advisors Series Trust | 0,04% | 9 NS | 31 Luglio 2026 | N-PORT |
| IYY · iShares Trust | 0,04% | 4.688 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,03% | 30.298 SH | 11 Settembre 2026 | Giornaliero |
| ITOT · iShares Trust | 0,03% | 141.099 SH | 11 Settembre 2026 | Giornaliero |
| PHDG · Invesco Actively Managed Exchange-T… | 0,03% | 88 SH | 02 Ottobre 2026 | Giornaliero |
| HCMT · Direxion Shares ETF Trust | 0,03% | 772 NS | 31 Luglio 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,03% | 3.515.122 SH | 19 Agosto 2026 | Giornaliero |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,03% | 18.213 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,03% | 9.300 SH | 19 Agosto 2026 | Giornaliero |
| SPXL · Direxion Shares ETF Trust | 0,03% | 8.650 NS | 31 Luglio 2026 | N-PORT |
| URTH · iShares, Inc. | 0,03% | 10.177 SH | 11 Settembre 2026 | Giornaliero |
| TILT · FlexShares Trust | 0,03% | 2.686 NS | 31 Luglio 2026 | N-PORT |
| TOK · iShares Trust | 0,03% | 292 SH | 11 Settembre 2026 | Giornaliero |
| ACWI · iShares Trust | 0,03% | 36.161 SH | 11 Settembre 2026 | Giornaliero |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,02% | 95.097 SH | 19 Agosto 2026 | Giornaliero |
| DYNF · BlackRock ETF Trust | 0,02% | 34.844 SH | 11 Settembre 2026 | Giornaliero |
| GTO · Invesco Actively Managed Exchange-T… | 0,00% | 1.000 | 30 Settembre 2026 | Giornaliero |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Luglio 2026 | Giornaliero |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Luglio 2026 | Giornaliero |
| VCEB · VANGUARD WORLD FUND | · | · | 30 Luglio 2026 | Giornaliero |
DGX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 23 analisti
COMPRA
Target mediano
$250.00
+7,1%
6 26,1%
Acquisto forte
7 30,4%
Compra
10 43,5%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
15 analisti · 2026-10-04Target medio $247.73 +6,2%
Ora
Prezzo attuale $233.33
Basso$204.00
Media$247.73
Alto$265.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | · |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | · |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | · |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| HIMS | · | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| CHE | · | 23.3 | 4.1% | 10.5% | 24.4% | · |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Lug 23, 2026